Clinical Trials Logo

Bioequivalence clinical trials

View clinical trials related to Bioequivalence.

Filter by:

NCT ID: NCT01984398 Completed - Bioequivalence Clinical Trials

Comparison of Two Formulations of Androxal

Start date: December 31, 2013
Phase: Phase 1
Study type: Interventional

To determine and compare the pharmacokinetics (PK) of a single dose of each of two formulations Androxal

NCT ID: NCT01638143 Completed - Bioequivalence Clinical Trials

Bio-equivalence Study

Start date: November 2010
Phase: N/A
Study type: Interventional

The primary objective of this study is to compare absorption of vitamin K2 (menaquinone-7) after intake of three different vitamin K2 supplements.

NCT ID: NCT01592019 Completed - Bioequivalence Clinical Trials

Clinical Study to Evaluate the Role of Microdialysis for the Comparison of Topical Products

Start date: April 2012
Phase: Phase 0
Study type: Interventional

The investigators hypothesize that a technique called microdialysis can be used to measure the amount of the drug diclofenac which penetrates (enters) the fatty tissue under the skin. Microdialysis uses a small device called a 'probe' to determine the amount of drug which enters a body tissue. The small device is placed directly in the fatty tissue and samples are taken at specific times. The investigators will determine whether site of application affects the availability of the drug.

NCT ID: NCT01340625 Completed - Bioequivalence Clinical Trials

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

Start date: December 2006
Phase: Phase 1
Study type: Interventional

This study compared the relative bioavailability (rate and extent of absorption) of 0.4 mg/35 mcg Norethindrone and Ethinyl Estradiol Chewable Tablets by Teva Pharmaceuticals, USA with that of 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets manufactured by Warner Chilcott Company, Inc., following a single oral dose (2 * 0.4 mg/35 mcg chewable tablets) in healthy female adult volunteers administered under fasting conditions.

NCT ID: NCT01331993 Completed - Healthy Volunteers Clinical Trials

A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation

Start date: September 2011
Phase: Phase 1
Study type: Interventional

The primary purpose is to demonstrate the bioequivalence of naproxen administered as VIMOVO manufactured at a new facility in Sweden (AstraZeneca) to that of naproxen administered as VIMOVO manufactured in the USA (Patheon) and to a marketed enteric-coated naproxen formulation.

NCT ID: NCT01260805 Completed - Bioequivalence Clinical Trials

A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.

Start date: September 2010
Phase: Phase 1
Study type: Interventional

A Phase I, Open Label, Randomized, Two-way Crossover, Single Dose Study to Determine the Bioequivalence of Ethinylestradiol + Gestodene - The objective of the study is to verify through a single dose study, if the two formulations of Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets are bioequivalent when administered at the same dose and under fasting conditions.

NCT ID: NCT01094847 Completed - Bioequivalence Clinical Trials

Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine

Start date: April 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare and explore bioavailability of mosapride, the main component of DWJ1252(Test drug) and mosapride medicine(Reference drug).

NCT ID: NCT00614029 Completed - Pharmacokinetics Clinical Trials

A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System

Start date: December 2006
Phase: Phase 1
Study type: Interventional

A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered by the Intraject system.